Information Provided By: 
Fly News Breaks for August 16, 2017
SUPN
Aug 16, 2017 | 07:56 EDT
Jefferies analyst David Steinberg says Supernus Pharmaceuticals' latest legal victory against TWi Pharmaceuticals reaffirms a positive outlook for the durability of the company's epilepsy franchise. Oxtellar XR cash flows are now secured over the next decade, Steinberg tells investors in a research note. Supernus could generate "very significant value" over the next five-to-ten years following the legal win and beat-and-raise Q2, the analyst adds. He keeps a Buy rating on the shares with a $51 price target.
News For SUPN From the Last 2 Days
There are no results for your query SUPN
